Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
MiniMax instructed the development of a research agent harness for an 'internal version of MiniMax M2.7' in order to develop the production version of MiniMax M2.7. The constructed agent harness can ...
Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
MiniMax Group Inc. designs and develops an artificial intelligence (AI) foundation model. The company's platform offers a wide range of modalities, including text, audio, images, video, and music. The ...
Threat actors abused trusted Trivy distribution channels to inject credential‑stealing malware into CI/CD pipelines worldwide ...
At its first developer conference, held in a former North Beach church, Perplexity unveiled Personal Computer, expanded its cloud agent to enterprise, opened up finance data tools, and staked its ...
Philips has officially unveiled its 2026 TV lineup, with new Ambilight-equipped models launching across its OLED and Mini LED ranges. The European AV company has confirmed the next generation of its ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results